

# Ribociclib with an aromatase inhibitor for adjuvant treatment of hormone receptor-positive HER2-negative early breast cancer at high risk of recurrence

Information for the public  
Published: 6 August 2025

[www.nice.org.uk](http://www.nice.org.uk)

Ribociclib (Kisqali) with an aromatase inhibitor is available on the NHS. It is a possible adjuvant treatment option for hormone receptor-positive, HER2-negative breast cancer in adults that:

- has not spread outside the breast (early) and
- has a high risk of coming back (recurrence).

An adjuvant treatment is one that is offered after surgery to lower the risk of the cancer coming back.

If you have not been through menopause, you will need to take ribociclib with a medicine that blocks the release of luteinising hormone (an LHRH agonist). This stops the ovaries making oestrogen and progesterone.

## Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. See [our webpage on making decisions about your care](#).

## Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

## Information and support

The NHS webpages on [breast cancer in women](#) and [breast cancer in men](#) may be a good place to find out more.

These organisations can give you advice and support:

- [Breast Cancer Now](#), 0808 800 6000
- [Independent Cancer Patients' Voice](#), [info@icpv.org.uk](mailto:info@icpv.org.uk)
- [Cancer Research UK](#), 0808 800 4040
- [Macmillan Cancer Support](#), 0800 808 0000

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-7108-4